The Ethiopian Ministry of Health and the Armauer Hansen Research Institute (AHRI) recently held a recognition ceremony to mark the successful completion of the “AHRI-001” (cAd3-Marburg) Phase II vaccine trial. This milestone highlights the effectiveness of clinical trials conducted during public health emergencies.
Leaders and experts who contributed significantly to the effectiveness of the work were honored with awards during the event. This historic achievement reaffirms Ethiopia’s capacity to deliver rapid, reliable, and evidence-based responses to global health crises.
Health Minister Dr. Mekdes Daba emphasized that This success is a significant contribution that Ethiopia has made to the international scientific community. “This achievement reflects not only progress but also responsibility. We have laid a solid foundation for building a competent, responsive, and prepared health system for future outbreaks,” the Minister stated.
The Marburg virus, known for its high mortality rate—ranging from 24% to 88%—remains one of the most formidable infectious diseases in medical history. When the outbreak occurred, with no approved vaccines or specific treatments available globally, Ethiopia’s decisive and swift action offered a beacon of hope. Ethiopia now stands as the second country in Africa to successfully conduct a Phase II clinical trial for a Marburg vaccine.
Professor Afework Kassu, Director General of AHRI, noted that the success demonstrates Ethiopia’s growing scientific maturity. “Courage in the face of a deadly outbreak. Science in service of humanity,” he remarked. He further explained that the rapid research model developed by Ethiopia provides a vital framework for responding to future health threats.
This vaccine trial project has equipped Ethiopia with the scientific tools necessary to confront health crises, positioning the nation as a model for the rest of Africa in using science to save lives. The institute remains committed to building upon this success and strengthening preparedness for any future health challenges.